Sciomics - About Us

The Power of Proteomics: Revolutionizing Science and Healthcare

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. 

At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to improve treatment with Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling.

We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). Our microarray platform, scioDiscover, is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its reliable results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout every stage of your project. Whether you need guidance, have questions, or require full-scale project support, we are committed to ensuring your success: 

Biomarkers_in_Precision_Medicine.jpg

Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. 

Technical Expertise: Our skilled team of professionals provides unmatched proficiency in your proteomic analysis endeavors.

Customized Solutions: We provide customized solutions to meet your specific research needs.  

Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report to provide a complete picture of your medical sample.

 

Our Platform Is Used For:

• Protein Biomarker Identification and Verification

• Novel Drug Target Discovery

• Mode-of-Action Analysis

• Pathway Activity Analysis

• Disease Model Characterization, among other key applications 

 

Join us on our mission to revolutionize medicine. Together, we can reshape the future of healthcare.

Meet us

RExPO25—Barcelona (Sept 24–26, 2025)

We are thrilled to be part of RExPO25 in Barcelona (September 24–26)—the 4th International Conference on Systems Medicine, AI & Drug Repurposing. Meet us there and stay tuned for insights we’ll bring back!

BIO-Europe 2025—Vienna (Nov 3–5, 2025)

Meet us at BIO-Europe 2025 in Vienna—where partnerships in biopharma innovation begin.

News

Article | Lactate-driven immune hotspots resolved via SLC5A12 blockade

| August 2025 | Lactate signaling induces cytokine production and T/B cell clustering in Sjögren’s disease, and SLC5A12 blockade reverses these effects. Sciomics contributed to this study by comparing protein abundance and acetylation levels of murine cells using the scioDiscover protein profiling platform.

Certo, M, et al.. Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution. Nat Metab. 2025;7(8):1663-1680.  
Article | ECM stabilisation drives rapamycin‑mediated lifespan extension in Marfan mgR/mgR mice

| May 2025 | Rapamycin extends lifespan in a Marfan syndrome mouse model by stabilising the extracellular matrix via increased ECM protein expression. Sciomics supported this study by identifying differentially expressed proteins in rapamycin-treated mice using the scioDiscover microarray platform.

Zaradzki et al., Stabilisation of extracellular matrix is crucial to rapamycin-mediated life span increase in Marfan mgR/mgR mice. Biochem Pharmacol. 2025;235:116830  
Article | Exploration of Novel Biomarkers for Neurodegenerative Diseases

| December 2024 | Biomarker candidates for neurodegenerative diseases were identified by combining an exploratory proteomic approach with quantitative ligand-binding assays. Sciomics supported this study by proteomic screening of plasma and CSF samples of patients with different neurodegenerative diseases using the scioDiscover microarray platform.

Kenzelmann A, et al.. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024;12(12):2794.  
Article | Altered Serum Proteins indicate Inflammation, Fibrogenesis and Angiogenesis in Fontan Patients

| September 2024 | Four identified serum proteins may advance diagnostic and therapeutic approaches by complementing traditional diagnostic laboratory variables. Sciomics contributed to this study by a scioCD serum analysis targeting different CD surface markers, cytokines and chemokines.

Michel M, Renaud D, Schmidt R, et al. Altered Serum Proteins Suggest Inflammation, Fibrogenesis and Angiogenesis in Adult Patients with a Fontan Circulation. International Journal of Molecular Sciences. 2024; 25(10):5416
 
Article | Vago-splenic signal transduction of cardioprotection in humans

| April 2024 | The spleen as a relay organ as well as the vagal innervation determine cardioprotective signal transduction of Remote Ischaemic Conditioning (RIC) and Auricular Tragus Stimulation (ATS). Sciomics contributed to this study by analysing plasma-dialysate samples using the scioDiscover microarray platform.

Lieder HR, Paket U, Skyschally A, et al. Vago-splenic signal transduction of cardioprotection in humans. Eur Heart J. 2024;45(34):3164-3177. 

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover